Schizophrenia Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Healthy volunteers (Work Package 1):

• People aged between 18 and 90 years old (the study aims to recruit 15 people aged 18–50 and 25 people aged 50–90)
• People judged to be in good general health by the study doctor, based on medical history, physical check-up, and lab tests
• People with no history or current signs of a major brain, nervous system, or mental health condition
• People who score 26 or higher on a standard memory and thinking test (called the MoCA) at the start of the study
• People under 60 years old who have a normal brain MRI scan as confirmed by a specialist radiologist
• People aged 60 or older who have only mild or no white matter changes on their brain scan (scored 2 or below out of 3 on a standard scale)
• People over 50 who are willing to provide a blood sample to test for a protein linked to Alzheimer's disease (called p-tau217)

People with a dementia diagnosis (Work Package 2):

• People who have a clinical diagnosis of early-stage Alzheimer's disease confirmed by biological markers

People with ALS (motor neurone disease) (Work Package 3):

• People who meet internationally recognised diagnostic criteria for at least a possible diagnosis of ALS (confirmed with trial site)

People with movement disorders (Work Package 4):

• All participants in this group: people (or their legal representative, where applicable) who are able to understand the study information and provide written consent
• Parkinson's disease: People with a clinically established Parkinson's disease diagnosis based on recognised specialist criteria, who also have an abnormal result on a specific brain scan (18F-PE2I PET), and who score 26 or higher on the MoCA thinking and memory test
• Multiple system atrophy (MSA): People with a confirmed or probable diagnosis of a specific type of MSA (MSA-P) based on specialist criteria, who also have an abnormal 18F-PE2I PET brain scan result
• Progressive supranuclear palsy (PSP): People with a confirmed probable PSP diagnosis based on the latest specialist criteria, and an abnormal 18F-PE2I PET brain scan result
• Dementia with Lewy bodies (DLB): People with a probable DLB diagnosis, meaning they have cognitive difficulties (MoCA score below 26) plus visual hallucinations and/or episodes of fluctuating alertness, and an abnormal 18F-PE2I PET brain scan result
• REM sleep behaviour disorder (iRBD): People with a confirmed diagnosis of iRBD through a specialised sleep study (polysomnography), who score 26 or higher on the MoCA test, and who show no signs of a movement disorder at the start of the study

People with psychosis (Work Package 5):

• People who meet recognised diagnostic criteria (DSM-5) for a schizophrenia-spectrum psychotic disorder that is not caused by mood disorder
• People aged 18–55 for adult-onset psychosis, or people aged over 60 whose psychosis began after age 60

Who may not be able to join:

• People who have a significant other medical, neurological, or psychiatric condition that could interfere with the study (such as serious liver or kidney disease, uncontrolled diabetes, cancer, severe depression, stroke, or serious brain injury)
• People who currently use or have a history of misusing illicit drugs (including cannabis) or alcohol
• People who regularly take medications that affect the brain or nervous system (such as strong opioid painkillers or antipsychotics), unless those medications are prescribed specifically for the condition being studied
• People who have already been exposed to ionising radiation above a certain level (more than 1 mSv) through other research studies in the past 12 months
• People who have a medical reason they cannot have an MRI scan
• People who experience claustrophobia or are unable to remain still inside a scanner for at least 60 minutes
• People (in the subgroup requiring arterial blood sampling only) who are allergic to a local anaesthetic called lidocaine, have poor blood flow in the forearm arteries (detected by a test called the Allen test), or who take blood-thinning medication
• People who are unable to understand what the study involves, either personally or through a legal representative
• People who are unwilling or unable to complete all study procedures, or who the lead researcher considers unsuitable for any reason
• People who may be pregnant (a pregnancy test may be carried out if there is any uncertainty)

Important: Always verify eligibility with the trial site directly before applying.